Prednisolone Phos-Bromfenac (prednisolone sodium phosphate/bromfenac sodium)

Ophthalmic NSAIDS Ophthalmic (EYE) Drops

Last reviewed October 24, 2026 · Source: First Databank (FDB) drug data

Overview

Bromfenac sodium is a prototypical nonsteroidal anti-inflammatory agent (NSAIA).

Prednisolone is a synthetic corticosteroid.

Bromfenac sodium is a prototypical NSAIA. The drug inhibits the synthesis of prostaglandins in body tissues by inhibiting cyclooxygenase (COX), including both COX-1 and COX-2 isoenzymes. The mechanism(s) of the ocular effects of NSAIAs appears to be associated principally with the inhibition of ocular prostaglandin synthesis.

By reducing ocular production of prostaglandins, NSAIAs can inhibit ocular inflammation and other reactions mediated primarily or secondarily by prostaglandins.

Generic name: prednisolone sodium phosphate/bromfenac sodium
Drug class: Ophthalmic NSAIDS
Therapeutic class: Ophthalmic Agents

Reference product & biosimilars

No reference, biosimilar or interchangeable associated with this drug.

Today’s intelligence on Prednisolone Phos-Bromfenac

Intelligence content is not available yet.

Indications

No indications are available for this drug.

Dosing

Dosage of bromfenac sodium, which is commercially available as the sesquihydrate, is expressed in terms of bromfenac.

The recommended adult dosage of bromfenac for the management of postoperative ocular inflammation and pain in patients who have undergone cataract extraction is 1 drop of a 0.09% solution in the affected eye(s) twice daily, beginning 24 hours after cataract surgery and continuing through the first 2 weeks of the postoperative period.

Potency of some sodium phosphate preparations is expressed in terms of prednisolone phosphate.

For use in the eye, 1 or 2 drops of prednisolone acetate ophthalmic suspension or prednisolone sodium phosphate ophthalmic solution may be instilled into the conjunctival sac every hour during the day and every 2 hours during the night for initial therapy in severe cases. In mild or moderate inflammation or when a favorable response is attained in severe cases, dosage may be reduced to 1 or 2 drops every 3-12 hours.

Alternatively, prednisolone sodium phosphate ophthalmic ointment may be instilled into the conjunctival sac 3 or 4 times daily initially, and once or twice daily thereafter. The ointment also may be used at night in conjunction with daytime use of a suspension or solution to reduce the frequent applications required with the liquid dosage forms.

The lowest effective concentration should be used and, if improvement does not occur within several days, the drug should be discontinued and other therapy begun. The duration of treatment depends on the type and severity of the disease and may range from a few days to several weeks; long-term therapy should be avoided. When the drug is discontinued, dosage should be gradually tapered to avoid exacerbation of the disease.

Drug interactions

No formal drug interaction studies have been performed to date.

Contraindications

Known hypersensitivity to bromfenac sodium or any ingredient in the formulation.

Adverse reactions

Adverse effects reported in 2% or more of patients receiving bromfenac sodium ophthalmic solution include abnormal ocular sensation, conjunctival hyperemia, ocular redness or irritation (e.g., pruritus, burning, stinging, pain), headache, and iritis.

Precautions

No enhanced messaging available.

ICD codes

No ICD codes are available for this drug.

Formulary status

Search health-plan coverage for this drug by ZIP code.

Enter a ZIP code to view available health plans.